📊 IBO Key Takeaways
Is IBO a Good Investment? Thesis Analysis
Impact Biomedical faces a critical liquidity crisis with only $3K in cash reserves while burning $1.9M annually in operating losses against virtually zero revenue ($32K). The company's current ratio of 0.35x indicates immediate inability to meet short-term obligations, and without significant capital injection or dramatic operational turnaround, faces existential viability risk.
Why Buy IBO? Key Strengths
- Minimal long-term debt exposure with no formal debt listed
- Positive stockholders equity of $12.6M provides modest balance sheet buffer
- Recent insider activity suggests management awareness of situation
IBO Investment Risks to Consider
- Critical liquidity crisis: only $3K cash with negative operating cash flow of -$1.9M
- Current ratio of 0.35x indicates inability to cover short-term liabilities
- Catastrophic profitability with -$4.3M operating loss against $32K revenue, unsustainable burn rate
- Negative free cash flow and margins indicate business model collapse or pre-revenue stage failure
Key Metrics to Watch
- Cash position and runway/months of liquidity remaining
- Revenue trajectory and product development pipeline progress
- Operating expense control and monthly cash burn rate
IBO Financial Metrics
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
IBO Profitability Ratios
IBO vs Healthcare Sector
How IMPACT BIOMEDICAL INC. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is IBO Overvalued or Undervalued?
Based on fundamental analysis, IMPACT BIOMEDICAL INC. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
IBO Balance Sheet & Liquidity
IBO 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: IMPACT BIOMEDICAL INC.'s revenue has declined by 36% over the 5-year period, indicating business contraction. The most recent EPS of $-2.30 indicates the company is currently unprofitable.
IBO Growth Metrics (YoY)
IBO Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $18.0K | -$1.5M | $0.03 |
| Q2 2025 | $7.0K | -$889.0K | $-0.09 |
| Q3 2023 | $50.0K | -$1.2M | $-0.02 |
| Q2 2023 | $50.0K | -$799.0K | $0.00 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
IBO Capital Allocation
IBO SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for IMPACT BIOMEDICAL INC. (CIK: 0001834105)
📋 Recent SEC Filings
❓ Frequently Asked Questions about IBO
What is the AI rating for IBO?
IMPACT BIOMEDICAL INC. (IBO) has an AI rating of STRONG SELL with 95% confidence, based on fundamental analysis of SEC EDGAR filings.
What are IBO's key strengths?
Claude: Minimal long-term debt exposure with no formal debt listed. Positive stockholders equity of $12.6M provides modest balance sheet buffer.
What are the risks of investing in IBO?
Claude: Critical liquidity crisis: only $3K cash with negative operating cash flow of -$1.9M. Current ratio of 0.35x indicates inability to cover short-term liabilities.
What is IBO's revenue and growth?
IMPACT BIOMEDICAL INC. reported revenue of $32.0K.
Does IBO pay dividends?
IMPACT BIOMEDICAL INC. does not currently pay dividends.
Where can I find IBO SEC filings?
Official SEC filings for IMPACT BIOMEDICAL INC. (CIK: 0001834105) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is IBO's EPS?
IMPACT BIOMEDICAL INC. has a diluted EPS of $-0.38.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is IBO a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, IMPACT BIOMEDICAL INC. has a STRONG SELL rating with 95% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is IBO stock overvalued or undervalued?
Valuation metrics for IBO: ROE of -93.9% (sector avg: 15%), net margin of -36,993.8% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy IBO stock in 2026?
Our dual AI analysis gives IMPACT BIOMEDICAL INC. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is IBO's free cash flow?
IMPACT BIOMEDICAL INC.'s operating cash flow is $-1.9M, with capital expenditures of N/A. FCF margin is -5,906.3%.
How does IBO compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -36,993.8% (avg: 12%), ROE -93.9% (avg: 15%), current ratio 0.35 (avg: 2).